Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Beijing Tong Ren Tang Chinese Medicine Co Debt-to-EBITDA Related Terms
Beijing Tong Ren Tang Chinese Medicine Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tong Ren Tang Chinese Medicine Co Debt-to-EBITDA Chart
Beijing Tong Ren Tang Chinese Medicine Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tong Ren Tang Chinese Medicine Co Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) has a Debt-to-EBITDA of 0.29 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beijing Tong Ren Tang Chinese Medicine Co. This is 123% above median its historical median of 0.13. According to the industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #143 out of 681 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Beijing Tong Ren Tang Chinese Medicine Co's Debt-to-EBITDA too high?
Beijing Tong Ren Tang Chinese Medicine Co's current Debt-to-EBITDA of 0.29 is 123% above median its 10-year median of 0.13. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Beijing Tong Ren Tang Chinese Medicine Co's value of 0.29 is 82.1% below this industry median. Based on the distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #143 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #143 out of 681 companies for Debt-to-EBITDA. This places Beijing Tong Ren Tang Chinese Medicine Co in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Beijing Tong Ren Tang Chinese Medicine Co's value of 0.29 is 82.1% below this benchmark. While the company's 10-year median is 0.13 vs. the industry median of 1.62, Beijing Tong Ren Tang Chinese Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tong Ren Tang Chinese Medicine Co's current Debt-to-EBITDA of 0.29 is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beijing Tong Ren Tang Chinese Medicine Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tong Ren Tang Chinese Medicine Co's current Debt-to-EBITDA is 0.29, which is 123% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) has a current Debt-to-EBITDA of 0.29. The stock's GF Value™ is $0.97, compared to a current price of $0.65 — trading 33.2% below its estimated fair value. The current Debt-to-EBITDA is 0.29, which is 123% above median its 10-year median of 0.13 and 82.1% below the Drug Manufacturers industry median of 1.62. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (BJTRF), the current Debt-to-EBITDA is 0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued.
The current stock price of $0.65 is trading 33.2% below its estimated GF Value™ of $0.97.
Key valuation signals for BJTRF:
Debt-to-EBITDA: 0.29 (123% above median its 10-year median of 0.13)
GF Value™: $0.97 vs. price of $0.65 (33.2% below fair value)
Industry Position: 82.1% below the Drug Manufacturers median (#143 of 681)
No single metric tells the full story. See the BJTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
88GF Score
Get the complete analysis for BJTRF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJTRF has been successfully added to your 
